Evofem Biosciences, Inc. filed a report regarding amendments to a merger agreement with Aditxt, Inc., and on August 22, 2025, agreed to exchange $1,573,000 in convertible notes for 1,573 shares of Series G-1 Convertible Preferred Stock. This indicates significant changes in its capital structure.